Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants

(2022) Vidya Perera et al.   CLINICAL PHARMACOKINETICS

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor

(2022) Vidya Perera et al.   Cardiology and Therapy

Cilostazol for secondary stroke prevention: systematic review and meta-analysis

(2021) Choon Han Tan et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Factor XI as a Target for New Anticoagulants

(2021) James C. Fredenburgh et al.   Hamostaseologie

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

(2021) Andrew K. Dilger et al.   JOURNAL OF MEDICINAL CHEMISTRY

First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor

(2021) Vidya Perera et al.   CTS-Clinical and Translational Science

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA

(2021) Yongjun Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Milvexian for the Prevention of Venous Thromboembolism

(2021) Jeffrey I. Weitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty

(2020) Jeffrey I. Weitz et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

(2020) Davide Capodanno et al.   Nature Reviews Cardiology

Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA

(2020) S. Claiborne Johnston et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke

(2020) Jessica L. Rohmann et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial

(2019) Mukul Sharma et al.   CIRCULATION

Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile

(2019) Jie Xu et al.   ANNALS OF NEUROLOGY

Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial

(2019) Kazunori Toyoda et al.   LANCET NEUROLOGY

Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes

(2019) Kanjana S. Perera et al.   JAMA Neurology

Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA

(2018) S. Claiborne Johnston et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetically Determined FXI (Factor XI) Levels and Risk of Stroke

(2018) Dipender Gill et al.   STROKE

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

(2017) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

(2015) Harry R. Büller et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Heidelberg Bleeding Classification

(2015) Rüdiger von Kummer et al.   STROKE

Embolic strokes of undetermined source: the case for a new clinical construct

(2014) Robert G Hart et al.   LANCET NEUROLOGY

Congenital Factor XI Deficiency: An Update

(2013) Stefano Duga et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Model-based dose finding under model uncertainty using general parametric models

(2013) José Pinheiro et al.   STATISTICS IN MEDICINE

Standardized Bleeding Definitions for Cardiovascular Clinical Trials

(2011) Roxana Mehran et al.   CIRCULATION

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

(2011) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduced incidence of ischemic stroke in patients with severe factor XI deficiency

(2008) O. Salomon et al.   BLOOD